15.02.2017

ARS initiates a local crossover two-period comparative study of pharmacokinetics, bioequivalence, and safety of Pazopanib, film-coated tablets, 200 mg, in patients with renal cell carcinoma. The clinical trial will be sponsored by the leading Russian pharmaceutical company.